Characterizing and treating cancers with an evolving and dynamic genome remains a challenge. BreakSight's vision is to help address this challenge and advance precision medicine by enabling the discovery of novel DNA sequence biomarkers of response to targeted cancer therapeutics and compounds. With one of the first commercial assays to identify DNA sequences associated with frequent DNA damage, our streamlined services can unveil site-specific maps of DNA breakage and reveal DNA-damaging mechanisms of cancer therapeutics with high resolution and specificity. DNA break signatures identified by our technology offer a greater understanding of DNA-damaging drugs, such as DDR inhibitors, the pathways that they target, and mechanisms of genomic instability previously left unchartered. Find out how your drug affects the genome and discover potentially new DNA biomarkers of drug response and efficacy.Our products:DDsite – o Performance of our BrITL assay to tag and retrieve DNA double-strand break sites across the genome from cells exposed to treatment(s) that induces DNA damage during proliferationo Performance of next-generation sequencing on captured DNA break fragmentsDDinsight –o Analysis of sequence data through our stringent analysis pipeline to pinpoint reproducible sites of breakage across the genomeo Uncover DNA repeats and sequence motifs that are enriched across identified DNA break siteso Compare sites across conditionsMore custom analysis can be performed upon request.